Cinacalcet

Cinacalcet

Error creating thumbnail: File missing
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	EU EMA: by INN US FDA: Cinacalcet
Pregnancy category	AU: B3 US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	H05BX01 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	20 to 25% Increases if taken with food
Protein binding	93 to 97%
Metabolism	Hepatic (CYP3A4-, CYP2D6- and CYP1A2-mediated)
Elimination half-life	30 to 40 hours
Excretion	Renal (80%) and fecal (15%)
Identifiers
IUPAC name N-[(1R)-1-(1-naphthyl)ethyl]-3- [3-(trifluoromethyl)phenyl]propan-1-amine
CAS Number	226256-56-0
PubChem CID	156419
DrugBank	APRD00872
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H22F3N
Molar mass	357.412 g/mol

WikiDoc Resources for Cinacalcet
Articles
Most recent articles on Cinacalcet Most cited articles on Cinacalcet Review articles on Cinacalcet Articles on Cinacalcet in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cinacalcet Images of Cinacalcet Photos of Cinacalcet Podcasts & MP3s on Cinacalcet Videos on Cinacalcet
Evidence Based Medicine
Cochrane Collaboration on Cinacalcet Bandolier on Cinacalcet TRIP on Cinacalcet
Clinical Trials
Ongoing Trials on Cinacalcet at Clinical Trials.gov Trial results on Cinacalcet Clinical Trials on Cinacalcet at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cinacalcet NICE Guidance on Cinacalcet NHS PRODIGY Guidance FDA on Cinacalcet CDC on Cinacalcet
Books
Books on Cinacalcet
News
Cinacalcet in the news Be alerted to news on Cinacalcet News trends on Cinacalcet
Commentary
Blogs on Cinacalcet
Definitions
Definitions of Cinacalcet
Patient Resources / Community
Patient resources on Cinacalcet Discussion groups on Cinacalcet Patient Handouts on Cinacalcet Directions to Hospitals Treating Cinacalcet Risk calculators and risk factors for Cinacalcet
Healthcare Provider Resources
Symptoms of Cinacalcet Causes & Risk Factors for Cinacalcet Diagnostic studies for Cinacalcet Treatment of Cinacalcet
Continuing Medical Education (CME)
CME Programs on Cinacalcet
International
Cinacalcet en Espanol Cinacalcet en Francais
Business
Cinacalcet in the Marketplace Patents on Cinacalcet
Experimental / Informatics
List of terms related to Cinacalcet

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. Cinacalcet is used to treat hyperparathyroidism (elevated parathyroid hormone levels), a consequence of parathyroid tumors and chronic renal failure.

Clinical uses

Cinacalcet is indicated for the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease on dialysis and hypercalcemia in patients with parathyroid carcinoma.

Dosage

Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease on Dialysis

The recommended starting oral dose is 30 mg once daily. Serum calcium and serum phosphorus should be measured within 1 week and PTH should be measured 1 to 4 weeks after initiation or dose adjustment of cinacalcet. It should be titrated no more frequently than every 2 to 4 weeks through sequential doses of 60, 90, 120, and 180 mg once daily to target iPTH consistent with the NKF-K/DOQI recommendation for CKD patients on dialysis of 150-300 pg/mL. PTH levels should be assessed no earlier than 12 hours after dosing with cinacalcet.

Cinacalcet can be used alone or in combination with vitamin D sterols and/or phosphate binders.

During dose titration, serum calcium levels should be monitored frequently and if levels decrease below the normal range, appropriate steps should be taken to increase serum calcium levels, such as by providing supplemental calcium, initiating or increasing the dose of calcium-based phosphate binder, initiating or increasing the dose of vitamin D sterols, or temporarily withholding treatment with cinacalcet.

Parathyroid Carcinoma

The recommended starting oral dose is 30 mg twice daily.

The dosage of cinacalcet should be titrated every 2 to 4 weeks through sequential doses of 30 mg twice daily, 60 mg twice daily, 90 mg twice daily, and 90 mg three or four times daily as necessary to normalize serum calcium levels.

NOTE: Cinacalcet should be taken whole and should not be divided. It should be taken with food or shortly after a meal.

Contraindications

• Hypersensitivity

External links

• Sensipar website run by Amgen
• Prescribing information
• Cinacalcet - Medlineplus.org
• Cinacalcet - Drug Digest.

Template:WikiDoc Sources